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Open access under CC BYThis study aimed to characterize osteoarthritis (OA)-related chronic pain and disability in experimental
cats with naturally occurring OA. Peak vertical ground reaction force (PVF), accelerometer-based motor
activity (MA) and the von Frey anesthesiometer-induced paw withdrawal threshold were used to deﬁne
OA and to test the efﬁcacy of meloxicam. A diagnosis of OA was based on radiographic and orthopedic
examinations. Cats with OA (n = 39) and classiﬁed as non-OA (n = 6) were used to assess the reliability
and sensitivity of the parameters to assess OA over 3 weeks while being administered placebo medica-
tion. A randomised parallel design study was then used to investigate the effects on OA of daily oral
meloxicam treatment for 4 weeks at different dose rates (0.025 mg/kg, n = 10 mg/kg; 0.04 mg/kg,
n = 10; 0.05 mg/kg, n = 9), compared to cats administered a placebo (n = 10).
The test–retest repeatability for each tool was good (intra-class correlation coefﬁcient P0.6). The PVF
and the von Frey anesthesiometer-induced paw withdrawal threshold discriminated OA (P < 0.05).
Meloxicam did not add to the PVF improvement observed in placebo-treated cats during the treatment
period (adj-P 6 0.01). The 0.025 and the 0.05 mg/kg meloxicam-treated cats experienced a higher
night-time (17:00–06:58 h) MA intensity during the treatment period compared to the placebo period
(adj-P = 0.04, and 0.02, respectively) and this effect was not observed in the placebo group. The high allo-
dynia rate observed in the 0.04 mg/kg meloxicam-treated group may explain the lower responsiveness to
the drug. The von Frey anesthesiometer-induced paw withdrawal threshold demonstrated no responsive-
ness to meloxicam. The results from this study indicated that daily oral meloxicam administration for
4 weeks provided pain relief according to night-time MA.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license. Introduction
Osteoarthritis (OA) in cats develops with aging and is responsi-
ble for causing disability and chronic pain (Hardie et al., 2002;
Lascelles, 2010; Slingerland et al., 2011; Bennett et al., 2012a).
While OA is very common in older cats, it is poorly diagnosed in
clinical practice (Clarke et al., 2005; Lascelles, 2010). This may be
related to the mismatch between an orthopedic evaluation and
the severity of OA structural changes, and/or the lack of validated
chronic pain assessment tools in cats (Clarke and Bennett, 2006;
Lascelles et al., 2012). Unfortunately, this situation leads to an ab-
sence of approved medication for the treatment of OA-associated
chronic pain in cats in North America (Lascelles and Robertson,
2010; Bennett et al., 2012b).Unit, Centre de recherche du
HUM), Notre-Dame Hospital,
1 514 890 8000x26658.
cy).
-NC-ND license. Assessment of chronic pain in animals is challenging. This chal-
lenge may be related to the need to consider the impact of pain on
physical disability and the associated changes that occur in the
central nervous system due to chronic pain. Quantiﬁcation of limb
impairment using the peak vertical ground reaction force (PVF) has
been used to objectively evaluate OA-associated pain/disability in
cats (Guillot et al., 2012). Moreover, in this species, OA induces a
decrease in owner-assessed daily activity, a reluctance to jump
and to walk up stairs, and other altered behaviors (Bennett and
Morton, 2009; Zamprogno et al., 2010; Slingerland et al., 2011).
Accelerometer-based motor activity (MA) assessment is a com-
plementary approach, which provides an objective quantiﬁcation
of functioning limitations related to OA-associated chronic pain
(Lascelles et al., 2007b, 2010; Guillot et al., 2012). Moreover, several
studies in humans suggest that mechanical allodynia is an essential
part of the OA-associated chronic pain assessment (Hendiani et al.,
2003; Imamura et al., 2008; Arendt-Nielsen et al., 2010).
It was hypothesized that PVF, MA and the von Frey anes-
thesiometer-induced paw withdrawal threshold would provide
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The objectives for this study were as follows: (1) to assess the reli-
ability and sensitivity (discriminatory ability) to OA of PVF, MA
monitoring, and von Frey anesthesiometer-induced pawwithdrawal
threshold testing; (2) to test the dose-dependent efﬁcacy of a non-
steroidal anti-inﬂammatory drug (NSAID), meloxicam, in OA cats
using these three objective techniques to assess chronic pain.Materials and methods
Cat selection and experimental protocol
The Institutional Animal Care and Use Committee approved the study protocol
(Rech-1482), and the Canadian Council on Animal Care Guidelines were followed
regarding the care and handling of the cats.
Experimental cats were selected based on a normal physical and neurological
evaluation, complete blood count, blood biochemical proﬁle, and urine analysis. A
thorough orthopedic examination was performed to detect changes in gait, posture,
and the presence of joint pain. Cats with limb deformities or signs of acute disease
were disqualiﬁed from the study. The cats were also screened using computed
radiographs (CR) of the mediolateral and caudocranial stiﬂe projections. The coxo-
femoral, carpal and tarsal joints as well as the mediolateral projection of shoulders
and elbows were also screened. These CRs were performed under intramuscular
sedation using medetomidine (0.02 mg/kg; Domitor 1 mg/mL, Pﬁzer Canada Animal
Health) and morphine (0.1–0.2 mg/kg; Morphine Sulfate Injection 10 mg/mL, San-
doz). The radiographic OA severity was graded as previously described (D’Anjou
et al., 2008; Guillot et al., 2012).
Of the 120 cats examined, 48 satisﬁed the inclusion criteria and were classed
into three different OA-status groups (Fig. 1), as follows: OA-status group 0 (non-
OA cats) consisted of young cats (three females and three males) with normal
orthopedic examinations and no radiographic OA; OA-status group 1 consisted of
19 female and 13 male cats with an abnormal orthopedic examination and radio-
graphic OA; OA-status-group 2 consisted of ﬁve female and ﬁve male cats with
abnormal orthopedic examinations but no radiographic OA (Table 1).
After 2 weeks of quarantine, the cats were housed together in two similar ded-
icated rooms (surface around 8  12 m). Cats were acclimatized for 4 weeks, which
included the following: (1) twice-weekly training for PVF assessment (to move
freely across the pressure sensitive mat, and to perform progressive stair exercises);
(2) von Frey anesthesiometer-induced paw withdrawal threshold testing; and (3)
1 week of conditioning to wear the accelerometer device. The room environment
and the cats’ health were controlled and recorded daily, and the cats were weighed
each week. The cats were fed according to the food manufacturer’s recommenda-
tions once daily in the afternoon with a standard certiﬁed commercial cat food
(Hill’s Prescription Diet w/d Feline). Water was supplied ad libitum. In both rooms,
the cats were allowed to move freely, with free access to toys, covers, height plat-
forms, and one large window. Beds in quiet locations were also freely accessible.
Initially, all cats received 3 weeks of the placebo (identical to Metacam Oral
Suspension without the active ingredient) orally once daily in the morning, thus
providing an acclimatization period for the drug administration. During this
placebo period, outcome reliability (repeatability and stability) and sensitivity
(discriminatory ability) to OA were assessed. The OA cats were then divided into
four treatment groups using a controlled randomization according to the PVF values
obtained during the placebo period, and the OA-status-group, providing homogeneousFig. 1. Study design diagram. For the treatment effect analyses, only 10 cats per treatmen
nine cats, due to three withdrawals as outlined in Results section.treatment groups on these criteria. Each group then received either meloxicam
(Metacam Oral Suspension 0.5 mg/mL, Boehringer Ingelheim Vetmedica) or placebo
(n = 11) for 4 weeks at the following dose rates: 0.025 mg/kg (n = 11); 0.04 mg/kg
(n = 10); 0.05 mg/kg (n = 10). Following the controlled randomization, each treat-
ment group was similarly represented in both living rooms. A 6 week recovery per-
iod occurred during which no treatment was administered to test the persistence
effects of the treatment. All evaluations of the OA status and the provided treatment
were conducted blindly (Fig. 1).Measurement of PVF
Peak vertical of the ground reaction force was acquired using a ﬂoor mat-based
plantar force measurement system (Walkway SystemWE4, Tekscan) and was man-
aged using Walkway Research software v.7.0. Prior to each kinetic measurement,
equilibration and calibration of the system was performed. The cats were coaxed
using positive reinforcement (treats, clicker, brushing, etc.) to trot across the walk-
way at a comfortable speed (0.8–1.4 m/s). Speed was computed by the software
using the time and distance of a given stride. Only the four-foot strikes of the ﬁrst
stride were considered. Among all kinetic gait parameters generated, only the max-
imal loading, referred to as the PVF, was considered, as supported by a previous
study (Guillot et al., 2012).
For each session, a maximum of three valid trials (the cat moved across the en-
tire mat undisturbed, consistently, in a straight line, and at the correct speed) were
obtained for each cat, with an a priori maximum of 16 consecutive trials allowed.
The number of trials needed to obtain the three valid trials was recorded. The
PVF was recorded before and immediately after approximately 3 min of stair exer-
cises. Stair exercises on a 10 m long staircase consisted of running up, down, and
then up again. The post-exercise measurement was performed within 60 s of the ﬁ-
nal excursion up the stairs.
Based on the PVF expressed as a percentage of bodyweight (% BW), the most af-
fected limb of the before and after-exercise sessions was determined for each cat.
The most affected limb was deﬁned as the limb that generated the lower PVF value
most frequently during a trial, among all of the analyzed trials during the placebo
period (maximum of 3  3 = 9 trials). If an equal number of lower values was de-
tected for each limb, the limb with the lower average PVF value was chosen. For
each day of evaluation, the kinetic gait analysis outcome of each session (before/
after exercise) was calculated by averaging the three valid trials of the most affected
limb PVF of each cat.Motor activity assessment
The MA was assessed using a collar-attached accelerometer-based activity sen-
sor (ActiWatch, Minimitter/Respironics, Bio-Lynx Scientiﬁc Equipment) maintained
in place from day (D) 21 to D69 (see Fig. 1). The device was set for local time and
conﬁgured to create 1 count value per 2 min. The amplitude of each count was sub-
sequently translated to a numeric value (from 0 to inﬁnite) referring to the intensity
count of MA. To exclude periods where human activity and handling interfered with
the cats’ activity, only 3 days per week (Friday, Saturday and Sunday), between
17:00 and 06:58 h, were considered for the analyses. This was supported by our pi-
lot study data (Guillot et al., 2012), where MA of OA cats was more affected during
night-time. Additionally, all adverse events were recorded and excluded. Data were
expressed as the average total intensity counts. Thus, for each week of evaluation,
the MA outcome was obtained for each cat by calculating the median of the three
periods.t group were kept, except in the 0.05 mg/kg meloxicam-treated group, which totaled
Table 1
Age, radiographic and orthopedic features of the selected cats at the start of the study by OA-status group.
Feature OA-status group
0 1 2
Mean age [SD] (year) 2.8 [1.4] 8.0 [2.4] 8.9 [1.4]
Median radiographic scores (range)
Forelimbs 0 (0–0) 1 (0–9) 0 (0–0)
Hind limbs 0 (0–0) 3 (0–11) 0 (0–0)
Median radiographic OA-affected joint number (range)
Forelimbs 0 (0–0) 1 (0–4)a 0 (0–0)
Hind limbs 0 (0–0) 2 (0–4)b 0 (0–0)
Presence of gait alteration (%) 0 43.7 40
Presence of posture alteration (%)
Forelimbs 0 9.4 10
Hind limbs 0 37.5 60.0
Presence of subjective pain as noted by a blinded observer (%)
Forelimbs 0 9.3 22.3
Hind limbs 0 100 100
a The affect joints in 32 cats were shoulder (12/32 = 37.5%), elbow (9/32 = 28.1%), and carpal (4/32 = 12.5%) joints.
b The affect joints in 32 cats were coxofemoral (21/32 = 65.6%), tarsal (12/32 = 37.5%), and stiﬂe (11/32 = 34.4%) joints.
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Secondary punctate allodynia responses were evaluated using gradually
increased pressure applied on the plantar paw surface with a mechanical von Frey
polypropylene probe (Rigid Tip 0.7 mm2 of surface 28 G, IITC Life Science) ﬁtted on
a hand-held force transducer and paw withdrawal threshold monitoring anesthesi-
ometer. The tip was placed perpendicularly to the plantar surface of each paw
(without manipulating the limb) in turn in a pre-deﬁned order while the cat was
standing up partially restrained in a meshed cage speciﬁcally designed for this eval-
uation. The stimulus was stopped as soon as the paw was withdrawn or the cat
showedpain behaviors, such as vocalisation, agitation, or avoidance. For each animal,
the peak of force in grams was recorded, and duplicate measurements of each paw
were obtained with a 60 s interval between both stimuli. The data under 2 g were
discarded, and a maximal cut-off value of 200 g was applied. For each evaluation
day, the von Frey anesthesiometer-induced paw withdrawal threshold outcome
was obtained by averaging all of the available threshold values (n = 8) for each cat.
In addition to these parameters, an allodynia threshold was set at 40 g for the
front paws and 50 g for the hind paws according to the data distribution. These
thresholds were determined based on the ﬁrst quartile values of the OA cats placebo
period data (lowest round value close to the mean of the 12 calculated ﬁrst quartile
values for the fore and hind paws respectively), and importantly, no non-OA cat pre-
sented such lowvalues, or lower, twice for aduplicate. A catwas considered tobe allo-
dynic if at least one of its paws presented duplicate values under the ﬁxed threshold.
Statistical method
All analyses were conducted two-sided with an a threshold of 0.05 using a sta-
tistical software program (SAS system, version 9.2). Outcome normality was veri-
ﬁed using the Shapiro–Wilk test.
During the placebo period, outcome repeatability was assessed by computing
the intra-class correlation coefﬁcient (ICC), a measure of the proportion of variance
that is attributable to objects of measurement. It is accepted that ICCs > 0.6 suggest
satisfactory, and >0.8 excellent stability (Faries and Yalcin, 2007). Mixed model
analyses for repeated measures allowing to model the covariance structure (Littell
et al., 2006) provided information about outcome stability over time (day effect
assessment) and the outcome ability to discriminate over an OA cat’s status (OA-
status-group effect estimates; whole model details are provided in Table 2). A Tu-
key–Kramer adjustment was used to obtain adjusted P-values (adj-P) for multiple
comparisons.
Mixed model analyses for repeated measures were also conducted to test the
effect of treatments on the different outcomes (whole model details are provided
in Table 2). To consider multiple comparisons, adjusted P-values were computed
using the Bonferroni correction (original P-value multiplied by the number of com-
parisons of interest, i.e., 3).Results
Departure from the protocol and health follow up
Punctate tactile allodynia was not evaluated for one cat in the
OA-status-group 0 because of constant non-reliable behaviorthroughout the placebo period. During the treatment period, three
OA cats (all of which originated from OA-status-group 1) were
withdrawn from the study. One 0.05 mg/kg meloxicam-treated
cat was withdrawn due to the occurrence of vestibular syndrome,
one 0.025 mg/kg meloxicam-treated cat was withdrawn because it
had chronic diarrhea, which required repeated isolation, and one
placebo-treated cat was withdrawn due to the development of
an aversion to being handled. Finally, there were 10 cats per treat-
ment group, except in the 0.05 mg/kg meloxicam-treated group,
which had nine cats.
No clinical side effects related to meloxicam administration
were observed in the 31 meloxicam-treated cats, no signiﬁcant
change in complete blood count, blood biochemistry or urine anal-
ysis was observed, and particularly, there were no individual in-
creases in liver or kidney parameters to values outside of the
normal range. However, data were discarded during the last week
of MA because the sensor stopped recording in the majority of cats
(75%) between D62 and D68 due to low batteries.
Outcome reliability and sensitivity to OA during the placebo period
The ICC (95% conﬁdence interval) of the most affected limb PVF
expressed as % BW before and after exercise was 0.49 (0.32–0.66)
and 0.60 (0.40–0.70), respectively. Moreover, mixed model analy-
ses showed no signiﬁcant change over time (days) of the most af-
fected limb PVF before and after exercise (P = 0.84 and 0.40
respectively), using BW (P < 0.01), velocity (P < 0.05) and the max-
imum number of trials (P < 0.01) as covariates. The ICC of the MA
was 0.87 (0.80–0.92), and no change over time was detected
(P = 0.33). Finally, the ICC of the von Frey anesthesiometer-induced
paw withdrawal threshold was 0.78 (0.67–0.87), and no change
over time was detected (P < 0.40).
The most affected limb PVF analyses before and after exercise
showed a signiﬁcant OA-status-group effect (P < 0.01 and P = 0.02,
respectively; Fig. 2A), with group comparison showing that the cats
in OA-status-group 1weremore affected. For the OA-status-group 1
cats (n = 29), all most affected limbs (pre and post exercise session)
werehind limbswith amedian (range) radiographic score of 2 (0–6),
27 (=93.1%) of which presented radiographic OA. Affected joints
were coxofemoral (18/27 = 66.7%), tarsal (8/27 = 29.6%), and stiﬂe
(6/27 = 22.2%) joints. For the OA-status-group 0 and 2 cats, all most
affected limbswere also hind limbs and, according to their selection
criteria,withno radiographicOA. TheMA intensitydemonstratedno
OA-status-group or interaction of day with OA-status-group effects
Table 2
Details of the mixed model analyses.
Modelsa,b Outcomes Outcome
transformationc
Fixed effects Covariance structures Covariatesd
Outcome variability
assessment and OA status
discrimination
PVF Log-
transformed
OA-status-group,
day, and their
interaction
Compound symmetry with a
heterogeneous selection
group
BW, velocity and
maximum number of
trials
Motor activity Log-
transformed
Toeplitz with a heterogeneous
selection group
–
Von Frey anesthesiometer-
induced paw withdrawal
threshold
– Type 1 autoregressive –
Treatment effect assessment PVF Log-
transformed
Treatment, period,
and their interaction
Compound symmetry BW, velocity and
maximum number of
trials
Motor activity Log-
transformed
Toeplitz with a heterogeneous
treatment group
–
Von Frey anesthesiometer-
induced paw withdrawal
threshold
Square root
transformed
Spatial power –
a All models used a mixed model method for repeated measures and provided ﬁxed effect estimates by restricted likelihood modeling. The homogeneity of variance was
assessed using the absolute values of the residuals of the mixed model, and the best structure of the covariance model was assessed using a graphical method (plots of
covariance vs. lag in time between pairs of observation compared to different covariance models), as well as using information criteria that measure the relative ﬁt of
competing covariance models. Also, residuals of the models were thoroughly studied to assess the model’s validity (Littell et al., 2006).
b All models used day as the repeated factor.
c Outcome transformations were recommended following residual analysis results.
d Covariates of the models were thoroughly assessed and only signiﬁcant ones were kept in each ﬁnal model.
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paw withdrawal threshold analyses indicated a signiﬁcant OA-
status-group effect (P = 0.02; Fig. 2C). Particularly for OA-status-
group 1 cats, the von Frey anesthesiometer-induced paw
withdrawal threshold was lower than that of the OA-status-group
0 cats (adj-P = 0.02).
Effect of meloxicam
The before-exercise PVF data were not considered to be ade-
quate to test for the effects of meloxicam because this outcome
was not sufﬁciently reliable and sensitive to OA, compared to the
after-exercise PVF data. Descriptive statistics for the different out-
comes over the evaluation days are provided in Table 3 (most af-
fected limb PVF after exercise and essential covariates: velocity
and maximum number of trials), Table 4 (MA) and Table 5 (von
Frey anesthesiometer-induced paw withdrawal threshold).
The most affected limb PVF after-exercise analyses indicated an
overall period effect (P < 0.01), but showed neither a signiﬁcant
treatment effect nor an interaction of treatment with period effect
(P > 0.30). After excluding the OA-status group 2 cats, complemen-
tary analyses of the most affected limb PVF after exercise showed
an overall period effect (P < 0.001) and no signiﬁcant treatment ef-
fect (P = 0.78). However, there was a signiﬁcant interaction of
treatment with period effect (P < 0.04). In particular, there was a
signiﬁcant increase in PVF for the 0.025 and 0.05 mg/kg meloxi-
cam-treated cats during the treatment compared to the placebo
period (adj-P < 0.01). The placebo-treated cats also experienced a
signiﬁcant increase in PVF between the placebo and the treatment
period (adj-P = 0.01) in these complementary analyses (Fig. 3).
The MA analyses revealed an overall period effect (P < 0.01) and
no signiﬁcant treatment effect (P = 0.35). However, there was a sig-
niﬁcant interaction of treatment with period effect (P < 0.01). There
was an increase in MA intensity of meloxicam, but not of placebo-
treated cats between the placebo and the treatment periods
(Fig. 4). The increase in MA intensity was signiﬁcant for the
0.025 and the 0.05 mg/kg meloxicam-treated cats (adj-P = 0.04,
and 0.02, respectively). Only in the group receiving the lowest dose
of meloxicam was their activity signiﬁcantly lower during the
recovery compared to the treatment period (adj-P < 0.01).Von Frey anesthesiometer-induced paw withdrawal threshold
analyses did not indicate a signiﬁcant period effect, a treatment ef-
fect, or an interaction of treatment with period effect (P > 0.66).
Interestingly, the 0.04 mg/kg meloxicam-treated cats presented
with a higher rate of allodynia during the treatment period
(Table 6). No treatment affected either the von Frey anesthesiom-
eter-induced paw withdrawal threshold (Table 5) or the rate of
allodynia (Table 6).Discussion
Despite the importance of reliability testing to validate outcome
measures, to our knowledge this study is the ﬁrst to report on the
reliability of kinetic gait analysis, accelerometer-based MA assess-
ment and von Frey anesthesiometer-induced paw withdrawal
threshold testing in cats. According to the obtained ICC, the PVF ex-
pressed as % BW test–retest reliability after exercisewas better than
that before exercise but overall was moderately good. The stability
of the PVF values over time, after correction for BW, velocity, and
themaximumnumber of trials, indicates that covariates are needed
to provide a reliable outcome measure. Investigating and consider-
ing such covariates could avoid the difﬁculty encountered when
comparing study results (Lascelles et al., 2007a; Guillot et al., 2012).
The cats used the lower end (around 5 PSI) of the working range
of the mat (0–125 PSI), requiring a speciﬁc calibration to ensure
accuracy in the measurement. System error was minimized by
optimizing the recording of the ﬂoor mat-based plantar force mea-
surement system. An equilibration proﬁle adapted for companion
animals was used, which compensates for the variation in individ-
ual sensel output, and the system was calibrated with a custom-
made device of similar weight and contact area to those of the fe-
line subjects. Although the accuracy of the calibration method may
be subject to questioning, the repeatability and stability of the data
were good to excellent, and hopefully the future will see the emer-
gence of a standardized approach and a mat adapted for cat sensi-
tivity. The MA intensity and the von Frey anesthesiometer-induced
paw withdrawal threshold ICC were very good, and these out-
comes were stable over time, demonstrating their good reliability
in cats.
Fig. 2. Least square means of the different outcomes by OA-status-group during the
placebo period. (A) Least square means of the log-transformed most affected limb
PVF and SEM by OA-status group before- and after-exercise gait sessions. Before
exercise, the PVF of the OA-status-group 1 cats was lower than that of the OA-status
group 2 cats (adjusted P-value [adj-P] < 0.01) and similar to that of the OA-status
group 0 cats (adj-P = 0.12). In contrast, the PVF of the OA-status-groups 2 and 0 cats
were similar (adj-P = 0.12). After exercise, the PVF of the OA-status group 1 cats was
lower than that of the OA-status groups 0 and 2 cats (adj-P = 0.02, and 0.03,
respectively). The PVF of the OA-status groups 2 and 0 cats was similar (adj-
P = 0.58); (B) least square means of the log-transformed motor activity and SEM by
OA-status group; (C) least square means of the von Frey anesthesiometer-induced
paw withdrawal threshold and SEM by OA-status group. The von Frey anesthes-
iometer-induced paw withdrawal threshold of the OA-status group 1 cats was
lower than that of the OA-status group 0 cats (adj-P = 0.02), but similar to that of
the OA-status group 2 cats (adj-P = 0.54). In contrast, the von Frey anesthesiometer-
induced paw withdrawal threshold of the OA-status groups 2 and 0 cats was similar
(adj-P = 0.44).
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the placebo period of the after exercise-PVF demonstrate that thisoutcome, in contrast to the before-exercise PVF, is able to discrim-
inate between the functional state of non-OA and OA cats. This re-
sult suggested that the after-exercise PVF objectively quantiﬁes
chronic pain-related disability associated with OA in cats, as previ-
ously reported in dogs (Moreau et al., 2011; Rialland et al., 2012)
and humans (Henriksen et al., 2010). The most affected limb PVF
method was employed as a proxy for the whole cat impairment be-
cause of the gait interdependency of limbs affected, or not, by OA.
Limb pressures of a given cat are biologically and statistically
dependent, requiring a speciﬁc approach to be analyzed. We deter-
mined that using the most affected limb PVF method was more
sensitive and easier to interpret than the use of a four dependent
limbs statistical model (data not shown). The vast majority
(93.1%) of cats in the OA-status group 1 presented an association
of radiographic OA score to the most affected limb PVF. We relate
the absence of unanimity to the recognized poor sensitivity of
radiographic quantiﬁcation of structural OA (Lascelles et al., 2012).
Our radiographic OA scoring method involves estimation of
osteophytes/entesophytes (0–3), subchondral sclerosis (0–3) and
effusion (0–1). It was found to have lower sensitivity to detect
structural OA than that of magnetic resonance imaging (MRI) in
cats (Guillot et al., 2012). For one cat in particular, despite the ab-
sence of lesions detected on radiographs, several OA lesions were
detected on the MR images (Guillot et al., 2012). Therefore, since
PVF is a reﬂection of the overall condition of the cat and is inﬂu-
enced by both biomechanical alteration and pain perception, it
seemed logical to include all cats presenting clinical signs of OA.
The controlled exercise may have increased the joint pain during
use or induced muscular fatigue in impaired limbs, or both. More-
over, the lower PVF values of the OA-status group 1, compared to
the OA-status group 2, suggested that the cats with OA radio-
graphic signs presented with more disability than those with only
some OA clinical signs. Hence, PVF and radiographic evidence of OA
should be considered as an interesting stratiﬁcation factor of pain-
related disability in future studies investigating OA in cats.
The OA-status group 1 cats presented a lower MA than the cats
of the other status groups during the placebo period. But these dif-
ferences were not signiﬁcant, which could be related to a lack of
power due to the high intra-group variability. This variability
may be explained by the behavior-dependent nature of the MA,
which makes inter-group comparison difﬁcult (Lascelles et al.,
2010; Milgram, 2011). This highlights the need to use each cat as
its own control in MA analyses.
The signiﬁcantly lower von Frey anesthesiometer-induced paw
withdrawal threshold of the OA-status group 1 compared to the
non-OA cats suggests that central sensitization (induced by contin-
uous and intense nociceptive input from the OA joint) is an under-
lying mechanism of pain in OA cats, as is already thought in
humans (Arendt-Nielsen et al., 2010; Mease et al., 2011; Woolf,
2011). To our knowledge, this is the ﬁrst report of involvement
of allodynia related to OA in cats.
Despite the increase in PVF in the meloxicam-treated cats, our
study failed to demonstrate a signiﬁcant effect of meloxicam
against placebo on this parameter. We hypothesized that chronic
pain associated with OA induces a decrease in the use of the af-
fected limb, leading to muscle atrophy and limb impairment over
time. However, this loss of function related to chronic pain may
have been progressively restored with the weekly exercise per-
formed by all cats, masking improvement attributable to the
meloxicam treatment. This exercise-related improvement is sug-
gested particularly by the PVF values in the placebo-treated cat
group. The increase in PVF was maintained up until the last
time-point of the recovery period.
The inclusion of OA-status-group 2 animals may have limited
our ability to show an improvement in PVF due to meloxicam be-
cause these animals were not impaired based on this parameter
Table 3
Mean and standard deviation (SD) of the most affected limb PVF, velocity and maximum number of trials (MT) of the after-exercise session by treatment group over days.
Grey shaded columns are evaluation days of the treatment period.
Fig. 3. Least square means and SEM of the log-transformed PVF by period and
treatment after excluding OA-status group 2 cats. The placebo, 0.025 and 0.05 mg/
kg meloxicam-treated cats presented a signiﬁcantly higher PVF during the
treatment compared to the placebo period (Least square means differ-
ence ± SEM = 0.07 ± 0.02, adjusted P-value [adj-P] = 0.01; Least square means
difference ± SEM = 0.08 ± 0.02, adj-P < 0.01; and 0.10 ± 0.02, adj-P < 0.01, respec-
tively). The treatment-placebo period difference observed in the 0.05 mg/kg
meloxicam group was close to signiﬁcance compared to the placebo group.
Moreover, the placebo and all of the meloxicam-treated cats demonstrated a
signiﬁcantly higher PVF during the recovery period compared to the placebo period
(adj-P 6 0.01): Least square means difference ± SEM = 0.08 ± 0.02, 0.10 ± 0.02;
0.06 ± 0.02; 0.12 ± 0.02 for the placebo-, the 0.025, 0.04 and 0.05 mg/kg meloxi-
cam-treated cats, respectively (n = 7, 7, 8, and 7, respectively). The pooled
meloxicam groups were close to demonstrating a signiﬁcant difference between
the treatment and the recovery period, but the placebo group was not.
Fig. 4. Least square means and SEM of the log-transformed MA intensity by period
and treatment. The placebo-treated cats presented similar MA intensity across the
periods (P > 0.5). The 0.025 and 0.05 mg/kg meloxicam-treated cats presented a
signiﬁcantly higher MA intensity during the treatment compared to the placebo
period (least square means difference ± SEM = 0.18 ± 0.06, adjusted P-value
[adj-P] = 0.04; and 0.25 ± 0.07, adj-P = 0.02, respectively), but the 0.04 mg/kg
meloxicam-treated cats presented a MA intensity that tended to be higher
during the treatment compared to the placebo period (least square means differ-
ence ± SEM = 0.13 ± 0.05; adj-P = 0.08). Moreover, the 0.025mg/kg meloxicam-treated
cats presented a signiﬁcantly lower MA intensity during the recovery compared to the
treatment period (least square means difference ± SEM = 0.19 ± 0.05; adj-P < 0.01).
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yses excluding the OA-status group 2 animals. These analyses indi-
cated a signiﬁcant improvement in PVF in the placebo and 0.025
and 0.05 mg/kg meloxicam-treated cats, which persisted during
the recovery period. Moreover, a greater relative improvement
during the treatment period was observed in the meloxicam-trea-
ted cats (+10.1%, and +14.2% in the 0.025, and 0.05 mg/kg meloxi-cam-treated cats, respectively), compared to +8.9% in the placebo-
treated cats. It is therefore possible that the improvement in limb
function, as reﬂected by the PVF, could be related to the weekly
exercise. However, improvements in limb function appeared great-
er with meloxicam treatment (particularly when focusing on
OA-status group 1 cats). The inability to demonstrate an improve-
ment in PVF in the 0.04 mg/kg meloxicam-treated cats may be ex-
plained by the higher rate of allodynia observed in this group
(Table 6).
The observed improvement in MA intensity at night (17:00–
06:58 h) following meloxicam administration suggested that there
Table 4
Mean and standard deviation (SD) of the motor activity intensity by treatment group over days.
The mean (SD) values presented at each day in the above table correspond to the mean-per-group of the median in motor activity intensities of the three different periods
collected over three consecutive days of the week, corresponding to the day indicated as such in the table. Grey shaded columns are evaluation days of the treatment period.
Table 5
Mean and standard deviation (SD) of the von Frey anesthesiometer-induced paw withdrawal threshold (g) by treatment group over days.
Grey shaded columns are evaluation days of the treatment period.
Table 6
Percentage of allodynic cats by treatment group over periods.
Treatment (from D0 to D27) Period (%)
Placebo Treatment Recovery
Placebo 27 27.5 37
Meloxicam 0.025 mg/kg 30 27.5 30
Meloxicam 0.04 mg/kg 27 42.5 33
Meloxicam 0.05 mg/kg 18.5 17 30
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peared reasonable to focus on the night-time period, based on pre-
vious results, including the study by Lascelles et al. (2010) who
used a randomized, controlled, blinded, parallel group design and
reported that activity signiﬁcantly increased in the test diet group
between 06:00 and 12:00 h. Furthermore, a pilot study in our own
laboratory (Guillot et al., 2012) showed that the MA of normal cats
was greater than that of OA cats during the night-time. Finally, it
appeared logical with regard to the experimental conditions of this
study to limit the MA intensity analysis to periods of time without
any interference with the cats’ activity. The hypothesis was, there-
fore, that such MA intensity analysis would reﬂect the treatment
effect, being the only between-group element of difference.
Whether the observed increase in activity during this limited per-
iod would represent a whole day beneﬁcial effect is unclear, and
will need further investigation.
The improvement in MA is in accordance with the results of a
preliminary study using meloxicam in cats with OA-related pain
(Lascelles et al., 2007b). In the present study, during the treatment
period compared to the placebo period, there was a signiﬁcant
increase in the MA intensity by +3.7% for the 0.025 mg/kg
meloxicam-treated group and +5.2% for the 0.05 mg/kg meloxi-
cam-treated group, which suggested a dose-related response.
Additionally, only the cats receiving the highest dose maintained
an increased MA intensity during the recovery period. There was
only a +2.9% increase in MA intensity in the 0.04 mg/kg meloxi-
cam-treated group, which was close to being signiﬁcant. The highrate of allodynic cats observed in this group may have also inter-
fered with the MA improvement related to meloxicam. It may have
also contributed to the higher intra-group variability encountered
in this group (larger estimated SEM).
The von Frey anesthesiometer-induced paw withdrawal thresh-
olds remained stable over time in all of the treatment groups,
which is in accordance with the presumed inefﬁcacy of NSAIDs
on allodynia. It may be interesting in the future to detect the pres-
ence of allodynia in OA patients since it could inﬂuence the re-
sponse to treatment, and particularly the lack of response to
NSAIDs. In contrast, some drugs that target central sensitization
(e.g. ionic channels or NMDA-receptor blockers, and serotonin/
adrenaline reuptake inhibitors) have been suggested to be efﬁca-
cious in relieving OA-associated pain in humans (Mease et al.,
2011; Woolf, 2011) and dogs (Malek et al., 2012). Using a multi-
modal approach, such drugs should be further tested as a comple-
mentary treatment with meloxicam in OA-associated chronic pain
in cats.
The true status of the OA-status group 2 remains unclear since it
was based on a subjective evaluation. We decided to include the
OA-status-group 2 cats because radiographs are not always able
to detect OA in cats (Freire et al., 2011; Guillot et al., 2012). Based
on the advanced age of these cats (their mean age was similar to
the OA-status-group 1 cats, see Table 1), epidemiological studies
suggested a high risk of OA, despite the absence of radiographic
signs (Freire et al., 2011; Bennett et al., 2012a). The OA-status-
group 1 cats presented lower PVF values than those of the OA-sta-
tus-group 2 cats during the placebo period, suggesting a normal
limb function of the latter. However, for both OA-status-groups,
there was a positive treatment response in the MA intensity in
the meloxicam-treated cats, and no response in the placebo-
treated cats as indicated by an exploratory analysis of individual
responses (data not shown). These results suggested that the
OA-status group 2 cats may represent early onset OA cats. To avoid
biases that could be associated with the introduction of the
different OA-status groups, we controlled the randomization for
treatment distribution in OA-groups.
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In OA cats, PVF, MA intensity and the von Frey anesthesiometer-
induced paw withdrawal threshold are reliable chronic pain evalu-
ation tools. Each of them reﬂects a distinct component of the
chronic pain syndrome, and as such they may be considered as
complementary in cat OA pain assessment. Daily oral meloxicam
administration of 0.025 and 0.05 mg/kg for 4 weeks signiﬁcantly
improved night-time (17:00–06:58 h) physical activity in cats suf-
fering from OA, which suggested that meloxicam provides clini-
cally relevant pain relief. However, meloxicam had no effect on
PVF or allodynia components, the latter being generally expected
from NSAIDs.
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